Oxyfedrine L-form HCl | CAS#16777-42-7 | adrenergic receptor agonist

MedKoo Cat#: 596453 | Name: Oxyfedrine L-form HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxyfedrine L-form HCl is a drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.

Chemical Structure

Oxyfedrine L-form HCl

CAS#16777-42-7

Theoretical Analysis

MedKoo Cat#: 596453

Name: Oxyfedrine L-form HCl

CAS#: 16777-42-7

Chemical Formula: C19H24ClNO3

Exact Mass:

Molecular Weight: 349.85

Elemental Analysis: C, 65.23; H, 6.91; Cl, 10.13; N, 4.00; O, 13.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Oxyfedrine L-form hydrochloride; Ildamen; D563; D 563; D-563; Modacor; Oxyfedrin; FDA 1576; L-Oxyfedrine hydrochloride;

IUPAC/Chemical Name

3-((1-hydroxy-1-phenylpropan-2-yl)amino)-1-(3-methoxyphenyl)propan-1-one hydrochloride

InChi Key

JMUPNNYLJGSMPK-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H23NO3.ClH/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2;/h3-10,13-14,19-20,22H,11-12H2,1-2H3;1H

SMILES Code

O=C(C1=CC=CC(OC)=C1)CCNC(C)C(O)C2=CC=CC=C2.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 349.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hayat S, Khalique G, Irfan M, Wani AS, Tripathi BN, Ahmad A. Physiological changes induced by chromium stress in plants: an overview. Protoplasma. 2012 Jul;249(3):599-611. doi: 10.1007/s00709-011-0331-0. Epub 2011 Oct 16. Review. PubMed PMID: 22002742. 2: Mazumdar K, Asok Kumar K, Dutta NK. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. Int J Antimicrob Agents. 2010 Oct;36(4):295-302. doi: 10.1016/j.ijantimicag.2010.05.003. Epub 2010 Jun 29. Review. PubMed PMID: 20591629. 3: Sukoyan GV, Antelava NA. Rational drug correction of systemic inflammatory response syndrome in severe experimental heart failure. Bull Exp Biol Med. 2009 Apr;147(4):411-4. English, Russian. PubMed PMID: 19704936. 4: Mazumdar K, Dutta NK, Kumar KA, Dastidar SG. In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biol Pharm Bull. 2005 Apr;28(4):713-7. PubMed PMID: 15802815. 5: Dzhanashiya PKh, Vladytskaya OV, Salibegashvili NV. Efficiency and mechanisms of the antioxidant effect of standard therapy and refracterin in the treatment of chronic heart failure in elderly patients with postinfarction cardiosclerosis. Bull Exp Biol Med. 2004 Oct;138(4):412-4. PubMed PMID: 15665959. 6: Kanorskii SG, Galenko-Yaroshevskii PA, Zingilevskii KB. Efficiency of refracterin in patients with chronic cardiac insufficiency caused by coronary heart disease. Bull Exp Biol Med. 2004 Jul;138(1):67-9. PubMed PMID: 15514727. 7: Mazumdar K, Ganguly K, Kumar KA, Dutta NK, Chakrabarty AN, Dastidar SG. Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride. Microbiol Res. 2003;158(3):259-64. PubMed PMID: 14521236. 8: Karsanov NV, Sukoian GV, Dzhibgashvili IK, Tatulashvili DR, Gorelishvili II, Guchua EI. [The subcellular pathophysiology of heart failure due to toxic-allergic myocarditis and the action of refracterin on intracardiac hemodynamics and the functional state of the 3 subcellular cardiomyocyte systems responsible for the act of contraction-relaxation]. Patol Fiziol Eksp Ter. 1999 Jul-Sep;(3):3-8. Russian. PubMed PMID: 10498985. 9: Zwicker K, Damerau W, Dikalov S, Scholtyssek H, Schimke I, Zimmer G. Superoxide radical scavenging by phenolic bronchodilators under aprotic and aqueous conditions. Biochem Pharmacol. 1998 Aug 1;56(3):301-5. PubMed PMID: 9744566. 10: Paleev NR, Sanina NP, Paleev FN, Pronina VP, Sukoian GV, Karsanov NV. [Chronic cardiac failure in noncoronarogenic myocardial diseases and refracterin effects]. Klin Med (Mosk). 1998;76(6):21-6. Russian. PubMed PMID: 9693495. 11: Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Jul;35(1):9-36. Review. PubMed PMID: 9673832. 12: Maulik SK, Seth SD, Maulik M, Manchanda SC. Oxyfedrine in myocardial stunning. Indian J Exp Biol. 1997 Nov;35(11):1214-7. PubMed PMID: 9567753. 13: Qu YZ, Wang YE, Li XX. Effects of thiofedrine on platelet aggregation, thromboxane B2 and 6-keto-PGF1 alpha in rats. Methods Find Exp Clin Pharmacol. 1996 Jun;18(5):297-300. PubMed PMID: 8817463. 14: Wetzelsberger N, Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D. Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Methods Find Exp Clin Pharmacol. 1995 Apr;17(3):185-91. PubMed PMID: 8531509. 15: Qu YZ, Li XX. Influence of thiofedrine on platelet aggregation, intraplatelet cyclic cAMP and malondialdehyde in rats. Methods Find Exp Clin Pharmacol. 1994 May;16(4):253-6. PubMed PMID: 8051984. 16: Yu J, Li XX. [Effects of oxyfedrine on high blood viscosity and myocardial necrosis induced by epinephrine and ice water stress in rats]. Zhongguo Yao Li Xue Bao. 1993 Jul;14(4):364-6. Chinese. PubMed PMID: 8249637. 17: Kaski JC, Araujo L, Maseri A. Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease. Cardiovasc Drugs Ther. 1991 Dec;5(6):991-6. PubMed PMID: 1801897. 18: Lantzsch W, Fikentscher R, Obrebowski A. [Ageusia as the aftereffect of oxyfedrine use]. Otolaryngol Pol. 1991;45(2):148-50. Polish. PubMed PMID: 2067860. 19: Alexander T, Krishnaswami S. Effect of intravenous oxyfedrine on exercise in patients with ischaemic heart disease. Indian Heart J. 1991 Jan-Feb;43(1):21-4. PubMed PMID: 1894296. 20: Gavrisiuk VK, Morskaia ND, Iachnik AI, Morozova NA, Iakhnitsia TV. [Use of beta 1-adrenostimulants in circulatory failure in patients with chronic inflammatory lung diseases]. Kardiologiia. 1990 Mar;30(3):32-5. Russian. PubMed PMID: 2199719.